We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$266M
AUM Growth
-$131K
Cap. Flow
+$22.7M
Cap. Flow %
8.52%
Top 10 Hldgs %
48.53%
Holding
95
New
9
Increased
25
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$7.86M
2
APLS
Apellis Pharmaceuticals
APLS
+$4.67M
3
TVRD
Tvardi Therapeutics
TVRD
+$4.02M
4
ALEC icon
Alector
ALEC
+$2.2M
5
MGNX icon
MacroGenics
MGNX
+$2.16M

Top Sells

Rank Stock Value
1
QNCX icon
Quince Therapeutics
QNCX
+$2.78M
2
INDP icon
Indaptus Therapeutics
INDP
+$1.8M
3
NXTC icon
NextCure
NXTC
+$1.44M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$1.41M
5
ARGX icon
argenx
ARGX
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 96.04%
2 Miscellaneous 3.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$48M 18.06%
13,680,554
– –
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$17.5M 6.58%
124,806
+1,000
+0.8% +$167K
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$12M 4.51%
636,013
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$9.05M 3.4%
123,218
– –
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$8.02M 3.01%
52,509
– –
ATRC icon
6
AtriCure
ATRC
$2.47B
$7.95M 2.99%
318,729
– –
FATE icon
7
Fate Therapeutics
FATE
$291M
$7.3M 2.75%
470,000
+409,969
+683% +$7.86M
TVRD
8
Tvardi Therapeutics
TVRD
$24.3M
$6.93M 2.61%
10,526
+4,831
+85% +$4.02M
IBB icon
9
iShares Biotechnology ETF
IBB
$10.5B
$6.46M 2.43%
64,900
+3,500
+6% +$366K
ASND icon
10
Ascendis Pharma A/S
ASND
$16.3B
$5.83M 2.19%
60,480
+1,100
+2% +$123K
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.7B
$5.81M 2.19%
64,508
-100
-0.2% -$9.34K
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$5.72M 2.15%
142,764
+2,000
+1% +$92.2K
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
$5.53M 2.08%
287,748
+82,308
+40% +$1.89M
DXCM icon
14
DexCom
DXCM
$34.3B
$5.42M 2.04%
145,352
– –
CYTK icon
15
Cytokinetics
CYTK
$10B
$4.76M 1.79%
418,727
-58,469
-12% -$734K
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.3M 1.62%
93,942
– –
LMNX
17
DELISTED
Luminex Corp
LMNX
$4.21M 1.58%
204,091
+10,000
+5% +$208K
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$4.09M 1.54%
+169,800
New +$4.67M
WVE icon
19
Wave Life Sciences
WVE
$993M
$4.06M 1.53%
197,554
-20,000
-9% -$459K
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.96M 1.49%
95,000
– –
YARW
21
Yarrow Bioscience
YARW
$98.8M
$3.84M 1.44%
238
+71
+43% +$1.15M
ARQL
22
DELISTED
Arqule Inc
ARQL
$3.8M 1.43%
530,262
+32,500
+7% +$305K
TBIO
23
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.61M 1.36%
364,229
+185,923
+104% +$1.76M
AKBA icon
24
Akebia Therapeutics
AKBA
$243M
$3.25M 1.22%
828,038
-2,500
-0.3% -$10.7K
XENE icon
25
Xenon Pharmaceuticals
XENE
$5.81B
$2.98M 1.12%
330,667
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, DAFNA Capital Management held 95 positions worth $266M, down 0.05% from $266M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management deployed $22.7M of net new capital in Q3 2019, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, an estimated $1.41M trimmed.

  • DAFNA Capital Management's largest Q3 2019 buy was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.
  • DAFNA Capital Management added most to Fate Therapeutics in Q3 2019, an estimated $7.86M increase.
  • DAFNA Capital Management's biggest Q3 2019 reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, cutting an estimated $1.41M.
  • DAFNA Capital Management fully exited Quince Therapeutics in Q3 2019, selling an estimated $2.78M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $266M portfolio in Q3 2019.
  • DAFNA Capital Management opened 9 new positions and closed 6 in Q3 2019.
  • DAFNA Capital Management's portfolio value fell 0.05% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.